Immunovaccine Disclaims Hoax Press Release

Share Article

Past News Releases

RSS

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV) has been made aware of a fraudulent press release disseminated this morning by PR Web, and redistributed by GlobeNewswire, purporting to be from Immunovaccine. This press release states that Immunovaccine has entered into a co-development agreement with Gilead Science, Inc. The press release did not originate from Immunovaccine and there is no accuracy to the information contained within the press release. Please note that all official statements by Immunovaccine are made via Marketwired.

About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

Connect at http://www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

-30-

Dr. Marc Mansour, Chief Executive Officer, Immunovaccine Inc.
T: (902) 492-1819 E: mmansour(at)imvaccine(dot)com

Tim Brons, Vida Strategic Partners (media)
T: (415) 675-7402 E: tbrons(at)vidasp(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Marc Mansour

Tim Brons
Vida Strategic Partners
415-675-7402
Email >
Visit website